Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

S-pseudotyped VLPs offer promising COVID-19 vaccine platform

A new study published on the preprint server bioRxiv* in September 2020 reports on a Moloney murine leukemia virus (MLV) platform that produces VLPs expressing the important spike antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Sep 2020

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

In a study published in the preprint server bioRxiv, researchers from the Kyoto Prefectural University of Medicine and Osaka University Japan, discuss how they engineered ACE2 to enhance its affinity to RBD in human cells.

17 Sep 2020

T cells on the front line of COVID-19 response

In the new study, published in the journal Cell, the team has found that the uncoordinated responses produced by the immune system, especially in people who are more than 65 years old, maybe the reason why older adults are more at risk.

17 Sep 2020

Ceftazidime flagged as a potential inhibitor of the SARS-COV-2 virus

After screening more than 3,500 FDA-approved drugs and small molecules, researchers at the Chinese Academy of Sciences found that ceftazidime, an antibiotic approved for use in treating pneumonia, binds to the receptors that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to in human cells.

17 Sep 2020

Study: T cells play a vital role in controlling SARS-CoV-2 during acute phase of infection

Ever since SARS-CoV-2 first appeared, researchers have been trying to understand whether sometimes the immune system does more harm than good during the acute phase of COVID-19. The latest study by researchers at La Jolla Institute for Immunology clearly argues in favor of the immune system.

17 Sep 2020

Optimal antibody combinations and Fc binding inhibit SARS-CoV-2 in vivo

A recent study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University and published on the preprint server bioRxiv in September 2020 shows that a combination of neutralizing antibodies with intact Fc effector function can effectively reduce the viral load and prevent infection.

17 Sep 2020

Seropositive partners increase risk of COVID-19 but not obstetric complications in pregnant women

While earlier studies have shown the significance of serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in pregnant women, their partners have largely been excluded. Now, a new Danish study published on the preprint server medRxiv in September 2020 reports the impact of serologic testing in both pregnant women and their partners, as well as their newborns.

17 Sep 2020

Blood viscometers could help guide the treatment of Covid-19 patients

One of the biggest challenges facing medical teams treating Covid-19 patients is identifying which ones are likely to suffer the most extreme responses to the virus.

17 Sep 2020

Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2

As the COVID-19 pandemic continues to cause an immense impact across many parts of the world, the role played by immune responses is becoming more evident every day. A recent funded paper published on the preprint server medRxiv* in September 2020 reports the initiation of a Phase I trial of a drug that increases antibody and cell-mediated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.

17 Sep 2020

Self-assembling nanoparticles as a way towards next-generation COVID-19 vaccines

In a promising study by US researchers, the receptor-binding domain (RBD) and stabilized spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were displayed on nanoparticles as vaccine antigens and elicited potent immune responses.

16 Sep 2020

Candidate monoclonal antibody shows hope as COVID-19 treatment

Researchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 Sep 2020

Critical insights into COVID-19 exposure for healthcare workers

A recent Northwestern University Feinberg School of Medicine study published in the preprint server medRxiv in September 2020 shows that the use of standard guidelines of infection control, including personal protective equipment (PPE), helps to prevent the undue risk of infection among HCWs as well.

16 Sep 2020

Study highlights role of specific protein in the mass production of antibodies

Antibodies play a fundamental role in medicine, and antibody-mediated immune response is the ultimate target in the quest for a vaccine to defeat the current pandemic.

16 Sep 2020

Researchers are testing the effectiveness of multiple treatments to prevent COVID-19

A study on the effectiveness of multiple treatments, including laboratory-made antibodies, at preventing mild COVID-19 from advancing to severe illness in the outpatient setting is underway by researchers at The University of Texas Health Science Center at Houston (UTHealth).

16 Sep 2020

SARS-CoV-2 infection severity linked to superior humoral immunity against the S-protein

In a recent bioRxiv* preprint paper, Jenna J. Guthmiller et al., focus on the acute infection of SARS-CoV-2 and observe that the humoral immunity is distinctive with the infection stage and viral antigens.

16 Sep 2020

Patients with more severe SARS-CoV-2 infection exhibit larger antibody response

Researchers in the United States have found that individuals who develop more severe disease following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mount a larger antibody and memory B cell response during both acute infection and convalescence.

15 Sep 2020

New nanomedicine is efficient and less aggressive than conventional prostate cancer therapy

Prostate cancer is the most common type of cancer among European men; its incidence surpasses 100 cases per 100,000 people.

15 Sep 2020

New antibody assay for COVID-19 promises sensitive mass-scale detection

A new paper by researchers at McMaster University and Hamilton Health Sciences, published on the preprint server medRxiv in September 2020, reports on the development of a serologic assay that is suitable for sensitive high-throughput antibody testing for COVID-19.

15 Sep 2020

Computational model can help identify best allocation plans for distributing test kits

Getting accurate, timely information on COVID-19 cases is one of the major challenges facing policymakers as they make decisions about public health and the economy.

15 Sep 2020